드라베 증후군 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연간 평균 성장률(CAGR) 8.7%로 성장할 전망이며, 5억 6,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 희귀질환에 대한 보험적용 확대, 환자증강증 증가, 유전자 검사의 저가격화, 희귀질환 치료에 대한 정부 지원 강화, 신경과 전문 클리닉 증가 등의 요인으로 인한 것으로 예측됩니다. 예측 기간 주요 동향으로는 발작제어를 위한 유전자 치료 발전, 조기진단을 위한 AI 이용 증가, 맞춤형 치료를 위한 정밀의료 개발, 간질 관리를 위한 약물 전달 시스템의 혁신, 원격 환자 모니터링을 위한 텔레헬스의 확대 등이 있습니다.
신경 질환의 유병률 증가는 드라베 증후군 시장의 성장을 가속할 것으로 예측됩니다. 신경 질환은 뇌, 척수, 신경계에 영향을 미치며 운동,인지, 감각 및 기타 신체 기능에 장애를 일으키는 광범위한 상태를 포함합니다. 이러한 질병은 인구 고령화, 라이프 스타일 변화, 환경 영향, 진단 방법 개선, 신경 감염 및 자가 면역 질환의 이환율 증가와 같은 요인으로 인해 더욱 흔해지고 있습니다. 드라베 증후군은 신경질환 연구를 진행하는데 중요한 역할을 하고 있으며, 유전자 변이, 뇌의 흥분성, 보다 광범위한 증상에 도움이 되는 표적 요법의 개발 등에 관한 귀중한 지견을 제공합니다. 예를 들어, 2022년 4월 유럽 뇌회의(European Brain Council)는 600개 이상의 신경질환과 300명의 정신질환이 세계 수백만 명에 영향을 미치고 있으며 간질만으로도 6,500만 명이 영향을 받고 있다고 보고했습니다. 유럽에서는 1,050만 명이 치매를 앓고 있으며, 2050년에는 1,870만 명으로 증가할 것으로 예측됩니다. 그 결과 신경 질환의 유병률 증가가 드라베 증후군 시장의 추진력이 되고 있습니다.
드라베 증후군 시장에 관련된 기업은 드라베 증후군의 근본적인 유전자 변이에 대처하고 치료 효과의 향상과 부작용의 최소화를 목표로 하는 표적 치료법을 개발하기 위해 RNA 기반 요법 등 정밀의료의 진보에 점점 주목하고 있습니다. RNA 기반 치료는 유전자 발현 및 단백질 생성을 변경하기 위해 RNA 분자를 사용하는 것을 포함하며, 분자 수준에서 근본적인 원인을 직접 표적으로 함으로써 유전 질환을 치료하는 방법을 제공합니다. 예를 들어 2024년 12월 미국의 생명공학 기업인 스토크세라퓨틱스사는 드라베 증후군 치료제인 조레뷰네슨의 미국 식품의약국(FDA) 승인을 획득했습니다. 이 치료제는 드라베 증후군 환자에게 많이 변이되고 있는 SCN1A 유전자의 발현을 증가시키도록 설계되었으며, 단순히 증상을 관리하는 것이 아니라 유전적 결손에 직접 대처합니다. RNA 기반의 정밀 의료를 이용함으로써 이 치료법은 적절한 신경세포 기능을 회복시키고 발작 빈도를 줄이며 인지 기능을 개선할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 드라베 증후군 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 드라베 증후군 시장 : 성장률 분석
- 세계의 드라베 증후군 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 드라베 증후군 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 드라베 증후군 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 드라베 증후군 시장 : 치료 및 관리별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 발작치료제
- 케토제닉 다이어트
- 미주 신경 자극
- 기타 치료 및 관리
- 세계의 드라베 증후군 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 자기 공명 화상 검사
- 뇌파 검사
- 나트륨 전위 의존성 채널 α 서브 유닛 1의 검사
- 기타 진단
- 세계의 드라베 증후군 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 비경구 경로
- 경구 경로
- 기타 투여 경로
- 세계의 드라베 증후군 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 제약회사
- 병원
- 진단실험실
- 학술연구기관
- 기타 최종 사용자
- 세계의 드라베 증후군 시장 : 발작 치료제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항경련제
- 벤조디아제핀
- 레베티라세탐
- 칸나비디올(CBD) 기반의 의약품
- 토피라마트
- 라모트리긴
- 세계의 드라베 증후군 시장 : 케토제닉 다이어트 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 표준 케토제닉 다이어트(SKD)
- 수정 앳킨스 다이어트(MAD)
- 저글리세믹 지수 치료(LGIT)
- MCT(중쇄 지방산 트리글리세리드) 다이어트
- 세계의 드라베 증후군 시장 : 미주 신경 자극 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 매립형 미주 신경 자극 장치(VNS)
- 비침습성 미주 신경 자극법(NIVNS)
- 발작 억제를 위한 VNS 보조요법
- 세계의 드라베 증후군 시장 : 기타 치료법 및 관리 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 물리치료 및 작업치료
- 언어요법
- 간질 수술
- 인지행동요법(CBT)
- 유전 상담 및 지원
제7장 지역별 및 국가별 분석
- 세계의 드라베 증후군 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 드라베 증후군 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 드라베 증후군 시장 : 경쟁 구도
- 드라베 증후군 시장 : 기업 프로파일
- Takeda Pharmaceutical Company Limited 개요, 제품 및 서비스, 전략 및 재무 분석
- Biogen Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- UCB SA 개요, 제품 및 서비스, 전략 및 재무 분석
- Eisai Co. Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Jazz Pharmaceuticals plc 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- H. Lundbeck A/S
- BioMarin Pharmaceutical Inc.
- PTC Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
- Zogenix Inc.
- Biocodex SA
- Encoded Therapeutics Inc.
- Marinus Pharmaceuticals Inc.
- Arvelle Therapeutics GmbH
- Stoke Therapeutics Inc.
- Longboard Pharmaceuticals Inc.
- Xenon Pharmaceuticals Inc.
- Aeovian Pharmaceuticals Inc.
- GW Pharmaceuticals plc
- Ovid Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 드라베 증후군 시장(2029년) : 새로운 기회를 제공하는 국가
- 드라베 증후군 시장(2029년) : 새로운 기회를 제공하는 부문
- 드라베 증후군 시장(2029년) : 성장 전략
제36장 부록
AJY
Dravet syndrome is a rare and severe form of epilepsy that begins in infancy, marked by frequent and prolonged seizures that are often resistant to treatment. It is commonly studied for its genetic link to mutations in the SCN1A gene and for developing targeted therapies aimed at managing seizure activity and improving patient outcomes.
The primary treatment options for Dravet syndrome include seizure medications, the ketogenic diet, vagus nerve stimulation, and other interventions. Seizure medications help prevent or reduce the frequency and intensity of seizures in conditions such as epilepsy and other neurological disorders. In addition to these treatments, diagnostic tests such as magnetic resonance imaging (MRI), electroencephalography (EEG), and sodium voltage-gated channel alpha subunit 1 testing are used. These treatments can be administered through various routes, including parenteral and oral options. The key end users include pharmaceutical companies, hospitals, diagnostic laboratories, and academic and research institutes.
The dravet syndrome market research report is one of a series of new reports from The Business Research Company that provides dravet syndrome market statistics, including the dravet syndrome industry global market size, regional shares, competitors with the dravet syndrome market share, detailed dravet syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the dravet syndrome industry. This dravet syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dravet syndrome market size has grown strongly in recent years. It will grow from $0.37 billion in 2024 to $0.40 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to factors such as the increasing prevalence of Dravet syndrome, improved diagnosis rates due to better screening methods, greater funding for epilepsy research, regulatory incentives for orphan drugs, and a higher acceptance of cannabis-based treatments.
The dravet syndrome market size is expected to see strong growth in the next few years. It will grow to $0.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as expanding insurance coverage for rare diseases, increasing patient advocacy, greater affordability of genetic testing, stronger government support for rare disease treatments, and a growing number of specialty neurology clinics. Key trends in the forecast period include advancements in gene therapy for seizure control, the rising use of AI for early diagnosis, the development of precision medicine for personalized treatments, innovations in drug delivery systems for epilepsy management, and the expansion of telehealth for remote patient monitoring.
The growing prevalence of neurological disorders is expected to drive the growth of the Dravet syndrome market. Neurological disorders encompass a wide range of conditions that impact the brain, spinal cord, and nervous system, leading to impairments in movement, cognition, sensation, or other bodily functions. These disorders are becoming more common due to factors such as aging populations, lifestyle changes, environmental influences, better diagnostic methods, and the increasing incidence of neuroinfections and autoimmune diseases. Dravet syndrome plays a significant role in advancing research into neurological disorders, offering valuable insights into genetic mutations, brain excitability, and the development of targeted therapies that could benefit a wider range of conditions. For example, in April 2022, the European Brain Council reported that more than 600 neurological diseases and nearly 300 psychiatric conditions affect millions of people worldwide, with epilepsy alone impacting 65 million individuals. In Europe, 10.5 million people suffer from dementia, with projections suggesting this number will rise to 18.7 million by 2050. Consequently, the growing prevalence of neurological disorders is helping to propel the Dravet syndrome market forward.
Companies involved in the Dravet syndrome market are increasingly focusing on advancements in precision medicine, such as RNA-based therapies, to create targeted treatments that address the genetic mutations underlying Dravet syndrome, aiming to improve treatment effectiveness and minimize side effects. RNA-based therapies involve the use of RNA molecules to modify gene expression or protein production, offering a way to treat genetic disorders by directly targeting the root causes at the molecular level. For example, in December 2024, Stoke Therapeutics Inc., a U.S.-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for zorevunersen, a treatment for Dravet syndrome. This therapy is designed to increase the expression of the SCN1A gene, which is commonly mutated in Dravet syndrome patients, directly addressing the genetic deficiency rather than simply managing the symptoms. By using RNA-based precision medicine, the therapy aims to restore proper neuronal function, potentially reducing the frequency of seizures and improving cognitive outcomes.
In March 2022, Union Chimique Belge (UCB), a Belgium-based pharmaceutical company, acquired Zogenix Inc. for $1.9 billion. This acquisition was intended to strengthen UCB's presence in the Dravet syndrome market by integrating Zogenix's expertise and its product FINTEPLA (fenfluramine) oral solution into UCB's neurology portfolio. The deal aims to increase global access to treatments for patients with severe epilepsy and explore additional indications to further solidify UCB's position in the field of rare neurological disorders. Zogenix Inc. is a U.S.-based company focused on developing therapies for rare diseases, including Dravet syndrome.
Major players in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, and Ovid Therapeutics Inc.
North America was the largest region in the dravet syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dravet syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dravet syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dravet syndrome market consists of revenues earned by entities that provide services such as advanced genetic screening, medical consultation and diagnosis, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The dravet syndrome market also includes sales of genetic testing kits, anticonvulsant medications, and emerging gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dravet Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dravet syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dravet syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dravet syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment And Management: Seizure Medications; Ketogenic Diet; Vagus Nerve Stimulation; Other Treatments And Management
- 2) By Diagnosis: Magnetic Resonance Imaging Testing; Electroencephalography Testing; Sodium Voltage-Gated Channel Alpha Subunit 1 Testing; Other Diagnosis
- 3) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration
- 4) By End-user: Pharmaceutical Companies; Hospitals; Diagnostic Laboratories; Academic And Research Institutes; Other End-users
- Subsegments:
- 1) By Seizure Medications: Anticonvulsants; Benzodiazepines; Levetiracetam; Cannabidiol (CBD) based medications; Topiramate; Lamotrigine
- 2) By Ketogenic Diet: Standard Ketogenic Diet (SKD); Modified Atkins Diet (MAD); Low Glycemic Index Treatment (LGIT); MCT (Medium Chain Triglyceride) Diet
- 3) By Vagus Nerve Stimulation: Implantable Vagus Nerve Stimulator (VNS); Non-invasive Vagus Nerve Stimulation (NIVNS); Adjunct Therapy With VNS For Seizure Control
- 4) By Other Treatments and Management: Physical and Occupational Therapy; Speech Therapy; Epilepsy Surgery; Cognitive Behavioral Therapy (CBT); Genetic Counseling And Support
- Companies Mentioned: Takeda Pharmaceutical Company Limited; Biogen Inc.; UCB S.A.; Eisai Co. Ltd.; Jazz Pharmaceuticals plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dravet Syndrome Market Characteristics
3. Dravet Syndrome Market Trends And Strategies
4. Dravet Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dravet Syndrome Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dravet Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dravet Syndrome Market Growth Rate Analysis
- 5.4. Global Dravet Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dravet Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dravet Syndrome Total Addressable Market (TAM)
6. Dravet Syndrome Market Segmentation
- 6.1. Global Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Seizure Medications
- Ketogenic Diet
- Vagus Nerve Stimulation
- Other Treatments And Management
- 6.2. Global Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Magnetic Resonance Imaging Testing
- Electroencephalography Testing
- Sodium Voltage-Gated Channel Alpha Subunit 1 Testing
- Other Diagnosis
- 6.3. Global Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Parenteral Route
- Oral Route
- Other Routes Of Administration
- 6.4. Global Dravet Syndrome Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmaceutical Companies
- Hospitals
- Diagnostic Laboratories
- Academic And Research Institutes
- Other End-users
- 6.5. Global Dravet Syndrome Market, Sub-Segmentation Of Seizure Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anticonvulsants
- Benzodiazepines
- Levetiracetam
- Cannabidiol (CBD) based medications
- Topiramate
- Lamotrigine
- 6.6. Global Dravet Syndrome Market, Sub-Segmentation Of Ketogenic Diet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Standard Ketogenic Diet (SKD)
- Modified Atkins Diet (MAD)
- Low Glycemic Index Treatment (LGIT)
- MCT (Medium Chain Triglyceride) Diet
- 6.7. Global Dravet Syndrome Market, Sub-Segmentation Of Vagus Nerve Stimulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Implantable Vagus Nerve Stimulator (VNS)
- Non-invasive Vagus Nerve Stimulation (NIVNS)
- Adjunct Therapy With VNS For Seizure Control
- 6.8. Global Dravet Syndrome Market, Sub-Segmentation Of Other Treatments and Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Physical and Occupational Therapy
- Speech Therapy
- Epilepsy Surgery
- Cognitive Behavioral Therapy (CBT)
- Genetic Counseling And Support
7. Dravet Syndrome Market Regional And Country Analysis
- 7.1. Global Dravet Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dravet Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dravet Syndrome Market
- 8.1. Asia-Pacific Dravet Syndrome Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dravet Syndrome Market
- 9.1. China Dravet Syndrome Market Overview
- 9.2. China Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dravet Syndrome Market
- 10.1. India Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dravet Syndrome Market
- 11.1. Japan Dravet Syndrome Market Overview
- 11.2. Japan Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dravet Syndrome Market
- 12.1. Australia Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dravet Syndrome Market
- 13.1. Indonesia Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dravet Syndrome Market
- 14.1. South Korea Dravet Syndrome Market Overview
- 14.2. South Korea Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dravet Syndrome Market
- 15.1. Western Europe Dravet Syndrome Market Overview
- 15.2. Western Europe Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dravet Syndrome Market
- 16.1. UK Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dravet Syndrome Market
- 17.1. Germany Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dravet Syndrome Market
- 18.1. France Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dravet Syndrome Market
- 19.1. Italy Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dravet Syndrome Market
- 20.1. Spain Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dravet Syndrome Market
- 21.1. Eastern Europe Dravet Syndrome Market Overview
- 21.2. Eastern Europe Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dravet Syndrome Market
- 22.1. Russia Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dravet Syndrome Market
- 23.1. North America Dravet Syndrome Market Overview
- 23.2. North America Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dravet Syndrome Market
- 24.1. USA Dravet Syndrome Market Overview
- 24.2. USA Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dravet Syndrome Market
- 25.1. Canada Dravet Syndrome Market Overview
- 25.2. Canada Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dravet Syndrome Market
- 26.1. South America Dravet Syndrome Market Overview
- 26.2. South America Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dravet Syndrome Market
- 27.1. Brazil Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dravet Syndrome Market
- 28.1. Middle East Dravet Syndrome Market Overview
- 28.2. Middle East Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dravet Syndrome Market
- 29.1. Africa Dravet Syndrome Market Overview
- 29.2. Africa Dravet Syndrome Market, Segmentation By Treatment And Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dravet Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dravet Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dravet Syndrome Market Competitive Landscape And Company Profiles
- 30.1. Dravet Syndrome Market Competitive Landscape
- 30.2. Dravet Syndrome Market Company Profiles
- 30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Jazz Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
31. Dravet Syndrome Market Other Major And Innovative Companies
- 31.1. H. Lundbeck A/S
- 31.2. BioMarin Pharmaceutical Inc.
- 31.3. PTC Therapeutics Inc.
- 31.4. Supernus Pharmaceuticals Inc.
- 31.5. Zogenix Inc.
- 31.6. Biocodex S.A.
- 31.7. Encoded Therapeutics Inc.
- 31.8. Marinus Pharmaceuticals Inc.
- 31.9. Arvelle Therapeutics GmbH
- 31.10. Stoke Therapeutics Inc.
- 31.11. Longboard Pharmaceuticals Inc.
- 31.12. Xenon Pharmaceuticals Inc.
- 31.13. Aeovian Pharmaceuticals Inc.
- 31.14. GW Pharmaceuticals plc
- 31.15. Ovid Therapeutics Inc.
32. Global Dravet Syndrome Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dravet Syndrome Market
34. Recent Developments In The Dravet Syndrome Market
35. Dravet Syndrome Market High Potential Countries, Segments and Strategies
- 35.1 Dravet Syndrome Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dravet Syndrome Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dravet Syndrome Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
